Print

Lay Description

This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.

Category

  • Diabetes
  • Minority Studies
IRB Number
20170647HU
NCT Number
NCT # not yet entered

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Principal Investigator
Joseph McCormick